CureToday: UC enrolling patients for glioblastoma trial
A new clinical trial at the University of Cincinnati is studying the effectiveness of a new two-pronged immunotherapy treatment procedure to treat the most aggressive and deadly type of brain tumors, called glioblastomas. Originating from healthy brain cells, glioblastomas can form in any area of the brain.
Soma Sengupta, MD, PhD, said the trial will administer two immunotherapy drugs in tandem with each other. She noted previous research has shown a single-arm immunotherapy treatment has not been effective, leading to the combination therapy being tested in the trial.
In collaboration with the Dana-Farber Cancer Insitute in Boston, a teaching affiliate of Harvard Medical School, researchers aim to enroll 24 patients in the Phase 1 study.
For more trial and enrollment information, contact Alex Love at lovea4@ucmail.uc.edu.
Featured photo at top of glioblastoma cells in culture courtesy of National Cancer Institute.
Related Stories
News Cincinnati loved in 2025
January 2, 2026
The story of prohibition bootlegger George Remus was among WLWT's favorite segments in 2025. UC Law Professor Christopher Bryant spoke with journalist Lindsay Stone about Remus using a temporary insanity defense during a murder trial.
What to know about this year’s big tax changes
January 2, 2026
Local 12 reported that taxpayers can expect some major changes this tax season. Gary Friedhoff, adjunct instructor at the University of Cincinnati’s Carl H. Lindner College of Business, recently spoke to Local 12 about how to avoid surprises.
Study finds police officers face higher long-term health risks
January 2, 2026
J.C. Barnes, a University of Cincinnati professor, is interviewed by Spectrum News about new research showing that the physical and psychological demands of law enforcement can contribute to earlier deaths.